Norio Katoh

Norio Katoh

Auto-generated profile, based on publicly available information

Norio Katoh

Department of Radiology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2008 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
NKNorio Katoh
Norio Katoh
RORikiya Onimaru
Rikiya Onimaru
YSYusuke Sakuhara
Yusuke Sakuhara
DADaisuke Abo
Daisuke Abo
SSShinichi Shimizu
Shinichi Shimizu
HSHiroki Shirato
Hiroki Shirato

22 December 2010 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
SOShunsuke Onodera
Shunsuke Onodera
HAHidefumi Aoyama
Hidefumi Aoyama
NKNorio Katoh
Norio Katoh
HTHiroshi Taguchi
Hiroshi Taguchi
KYKouichi Yasuda
Kouichi Yasuda
HSHiroki Shirato
Hiroki Shirato
To investigate the outcome of linac-based fractionated stereotactic radiotherapy over the last 10 years for intracranial skull base benign meningiomas in patients who were inoperable, who had residual tumors with some components of high mitotic index after surgery and who experienced relapse of the tumor. Twenty-seven patients with intracranial skull base benign meningiomas treated with fractionated stereotactic radiotherapy were retrospectively reviewed. Twenty-seven cases were diagnosed as benign meningiomas on pathological (17 cases) or radiological (10 cases) examination. The median follow-up time was 90 months after initial treatment and 63 months after fractionated stereotactic radiotherapy. The median biological equivalent dose calculated using an α/β ratio of 2.0 Gy was 82.0 Gy (range, 60–106 Gy). The 5-year overall survival was 95.7 (95% confidence interval: 87.3–100)% after initial treatment and 96.2 (88.8–100)% after fractionated stereotactic radiotherapy. The 5-year overall survival and local control rate of patients who received fractionated stereotactic radiotherapy alone were both 100%. The 5-year progression-free survival and local control rate after fractionated stereotactic radiotherapy were all 100% with a tumor volume of <9.1 cc and 68.2 (37.2–99.2) and 75.8 (45.2–100)% for the tumors 9.1 cc, respectively. The difference was significant in progression-free survival (P = 0.022) and local control rate (P = 0.044). The local control rate was significantly worse in patients who received fractionated stereotactic radiotherapy for relapsed tumors (P = 0.01). No late radiation damage was observed in the follow-up period. The long-term outcome suggests that fractionated stereotactic radiotherapy is a safe and effective treatment for intracranial skull base benign meningioma, especially for those who have tumors <9.1 cc or would receive fractionated stereotactic radiotherapy with or without surgery as the initial treatment.

14 May 2012 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
PDF file
KYKoichi Yasuda
Koichi Yasuda
RORikiya Onimaru
Rikiya Onimaru
OSOkamoto Shozo
Okamoto Shozo
TSTohru Shiga
Tohru Shiga
NKNorio Katoh
Norio Katoh
HSHiroki Shirato
Hiroki Shirato

1 January 2011 in Toukeibu Gan
Verified
Journal Article
Closed access
PDF file
RORikiya Onimaru
Rikiya Onimaru
KYKoichi Yasuda
Koichi Yasuda
NKNorio Katoh
Norio Katoh
HSHiroki Shirato
Hiroki Shirato
TSTohru Shiga
Tohru Shiga
SFSatoshi Fukuda
Satoshi Fukuda
陽電子放射断層撮影(Positron emission tomography, PET)検査では機能・代謝情報を得ることができる。PETによる低酸素イメージングで得られた情報を放射線治療に応用し,放射線抵抗性を示す腫瘍内の低酸素領域への線量増加をしようという試みも報告されている。北海道大学病院では,核医学診療科が中心となってdetectorに半導体を用いたPETを開発し,臨床に用いている。また,[18F]fluoromisonidazole(FMISO)PETによる低酸素イメージングも行われており,それを用いた強度変調放射線治療(Intensity modulated radiation therapy, IMRT)を用いた線量増加についても検討を始めている。本シンポジウムでは,北海道大学病院での放射線治療におけるPETの利用について,上記の項目を中心に発表する。